TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30085148

Group type: EXPERIMENTAL
Intervention: Biopsychosocial prevention course (11 classes on body posture and psychosocial aspects)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Physical activity promotion (5 classes according to national guidelines)
Number of subjects: 170
Study: 26785637

Group type: EXPERIMENTAL
Intervention: TXT2BFiT program (multi-component lifestyle program)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Coaching calls, text messages, emails
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Website and app
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Overall program components
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Post-intervention follow-up
Number of subjects: 214
Study: 24664539

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (4%) pretreatment
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Oral tramadol (50-mg) pretreatment
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 122
Study: 22620493

Group type: EXPERIMENTAL
Intervention: Immediate low vision rehabilitation intervention (1-2 weeks after enrollment)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed intervention (control) (3 months after enrollment)
Number of subjects: 100
Study: 19072827

Group type: EXPERIMENTAL
Intervention: HCV796 (a selective nonstructural protein 5B polymerase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCV796 monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCV796 in combination with interferon (30 mg/kg three times per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCV796 in combination with pegylated interferon and ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCV796
Number of subjects: 0
Study: 17393073

Group type: EXPERIMENTAL
Intervention: Triapine® (96 mg/m2 2‐h infusion daily for 4 days, repeated every 2 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Triapine®
Number of subjects: 19
Study: 16531503

Group type: EXPERIMENTAL
Intervention: Random group condition with Chips
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: Network condition with Chips
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: Teacher condition with Chips
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: Random group condition with Flavor
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: Network condition with Flavor
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: Teacher condition with Flavor
Number of subjects: 1486

Group type: COMPARATOR
Intervention: Curriculum and assignment methods
Number of subjects: 1486
Study: 12825566

Group type: EXPERIMENTAL
Intervention: 1 mg oxycodone
Number of subjects: 0
Study: 11036451

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 8634808

Group type: EXPERIMENTAL
Intervention: 70% glycolic acid peels
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10% glycolic acid-based moisturizer (twice daily)
Number of subjects: 12
Study: 1626678

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with oxybuprocaine 0.4%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 0
Study: 6196841

Group type: EXPERIMENTAL
Intervention: Cefotaxime (Claforan) given peroperatively and daily for five days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Methenamine (Hiprex) given daily from the day before the operation for a total of six days
Number of subjects: 42
Study: 31600363

Group type: EXPERIMENTAL
Intervention: Sorafenib plus Doxorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 0
Study: 30318332

Group type: EXPERIMENTAL
Intervention: Intra-articular implantation of 40 × 10^6 autologous bone marrow-derived mesenchymal stromal cells (MSCs)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (5 mL normal saline)
Number of subjects: 43
Study: 28052810

Group type: COMPARATOR
Intervention: Standard repair
Number of subjects: 2474

Group type: EXPERIMENTAL
Intervention: Mesh inlay
Number of subjects: 2474

Group type: EXPERIMENTAL
Intervention: Biological graft
Number of subjects: 2474

Group type: EXPERIMENTAL
Intervention: Mesh
Number of subjects: 2474

Group type: EXPERIMENTAL
Intervention: Graft
Number of subjects: 2474

Group type: EXPERIMENTAL
Intervention: Mesh kit
Number of subjects: 2474
Study: 24503679

Group type: EXPERIMENTAL
Intervention: Allograft plus autologous bone marrow concentrate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Autologous iliac crest bone
Number of subjects: 24
Study: 22906114

Group type: EXPERIMENTAL
Intervention: Early orthodontic treatment (initial maxillary expansion and subsequent activator therapy)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no early orthodontic treatment)
Number of subjects: 77
Study: 21178929

Group type: EXPERIMENTAL
Intervention: 8-week active stretching program
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Post-stretching program
Number of subjects: 18
Study: 16940468

Group type: EXPERIMENTAL
Intervention: 2-hour midafternoon nap (1400-1600) after a night of sleep loss
Number of subjects: 41
Study: 15578048

Group type: COMPARATOR
Intervention: Lower levels of beta-carotene in hypertensive participants compared to normotensive participants.
Number of subjects: 415

Group type: COMPARATOR
Intervention: Higher levels of uric acid in hypertensive participants compared to normotensive participants.
Number of subjects: 415

Group type: COMPARATOR
Intervention: Higher levels of malondialdehyde (MDA) in hypertensive participants compared to normotensive participants.
Number of subjects: 415
Study: 12394122

Group type: EXPERIMENTAL
Intervention: Radioactive iodine treatment (I-131)
Number of subjects: 71
Study: 9920085

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (200 mg/week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7755383

Group type: EXPERIMENTAL
Intervention: AO-90 (500-750 mL/day)
Number of subjects: 138

Group type: COMPARATOR
Intervention: C/MF (Amiparen, 600-800 mL/day)
Number of subjects: 138
Study: 2251028

Group type: EXPERIMENTAL
Intervention: High-fat semielemental diet (60% of fat as medium-chain triglycerides)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard semielemental diet (Pregestimil)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both diets (High-fat and Standard)
Number of subjects: 50
Study: 6118944

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine and Ranitidine
Number of subjects: 0
Study: 30772866

Group type: EXPERIMENTAL
Intervention: Topical intranasal tranexamic acid (TXA)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Indistinguishable placebo
Number of subjects: 450
Study: 27995674

Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy (CAT), 24 sessions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 18
Study: 25661397

Group type: EXPERIMENTAL
Intervention: Adaptive stand-alone working memory training
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 98
Study: 24727369

Group type: EXPERIMENTAL
Intervention: Online smoking intervention with testimonials
Number of subjects: 1865

Group type: COMPARATOR
Intervention: Online smoking intervention without testimonials
Number of subjects: 1865
Study: 21178181

Group type: EXPERIMENTAL
Intervention: 4% Ca salts of palm oil fatty acids (DM basis)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 6% Ca salts of palm oil fatty acids (DM basis)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (0.052 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (0.103 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (0.155 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CCK infusion (0.069 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CCK infusion (0.138 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CCK infusion (0.207 µg•kg of BW(‐1)•d(‐1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Feeding fat
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CCK infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (0% added fat)
Number of subjects: 18
Study: 18515460

Group type: EXPERIMENTAL
Intervention: Aripiprazole (5-15 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Naltrexone (50 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 75

Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 75
Study: 17709994

Group type: EXPERIMENTAL
Intervention: rTMS + CIT (n = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham rTMS + CIT (n = 10)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (rTMS + CIT and Sham rTMS + CIT)
Number of subjects: 19
Study: 14986114

Group type: EXPERIMENTAL
Intervention: 1G/2G genotypes in gastric cancer patients
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Histological differentiation in gastric cancer patients
Number of subjects: 215
Study: 12397863

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Left dorsolateral pre-frontal cortex (DLPFC) stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Left DLPFC stimulation in a parallel-groups design
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study: 9704771

Group type: EXPERIMENTAL
Intervention: Misoprostol (Cytotec)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 200
Study: 7774313

Group type: EXPERIMENTAL
Intervention: 10 mg metaproterenol aerosol pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: No bronchodilator
Number of subjects: 10
Study: 3291110

Group type: EXPERIMENTAL
Intervention: Ribomunyl aerosol (n = 19)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ribomunyl aerosol and injections (n = 17)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 53
Study: 30633776

Group type: EXPERIMENTAL
Intervention: 2012 RCT preparation costs
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 2016 RCT preparation costs
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 2012 REC approval time for single centre RCTs
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 2016 REC approval time for single centre RCTs
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 2012 Swissmedic approval time for any clinical trial
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 2016 Swissmedic approval time for any clinical trial
Number of subjects: 66
Study: 29231500

Group type: EXPERIMENTAL
Intervention: Electroacupuncture applied to Zhongji (CV 3) and Qugu (CV 2), once a day, 5 times a week for 6 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride sustained-release capsules, 0.2 mg, once a day for 6 weeks.
Number of subjects: 60
Study: 26619557

Group type: EXPERIMENTAL
Intervention: 5 mg desloratadine tablets
Number of subjects: 24
Study: 23938097

Group type: EXPERIMENTAL
Intervention: 20% price discount on fruit, vegetables, water and diet soft-drinks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined price discount and in-store nutrition education strategy
Number of subjects: 20
Study: 21226918

Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional open esophagectomy
Number of subjects: 120
Study: 18071677

Group type: EXPERIMENTAL
Intervention: CCKb receptor agonist pentagastrin (0.1 microg/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: mu-opioid receptor agonist remifentanil (0.0625 microg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 13
Study: 16826100

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐coated (HA) ProxiLock femoral hip prostheses
Number of subjects: 42

Group type: COMPARATOR
Intervention: Titanium (Ti) ProxiLock femoral hip prostheses
Number of subjects: 42
Study: 14587169

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral glycoprotein IIb/IIIa receptor antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 0
Study: 15239621

Group type: EXPERIMENTAL
Intervention: Sirolimus (target trough level 10-15 ng/mL)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Tacrolimus (target trough level not specified)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sirolimus (first phase)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sirolimus (second phase, after excluding obese recipients)
Number of subjects: 77
Study: 10510985

Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study: 8573755

Group type: EXPERIMENTAL
Intervention: Intensified care (IC) - hypertension teaching and treatment program based on blood pressure self-monitoring
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care (RC) - routine antihypertensive therapy
Number of subjects: 100
Study: 2232966

Group type: EXPERIMENTAL
Intervention: Combined chemo-immunotherapy with thymopentin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Only chemotherapy
Number of subjects: 115
Study: 326097

Group type: EXPERIMENTAL
Intervention: Pyridinolcarbamate (1.5 g thrice daily for 4 weeks)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Inositol niacinate (1.2 g thrice daily for 4 weeks)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Pyridinolcarbamate (1.5 g thrice daily for 6 weeks)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Inositol niacinate (1.2 g thrice daily for 6 weeks)
Number of subjects: 227
Study: 31944823

Group type: EXPERIMENTAL
Intervention: Hb below the reference range
Number of subjects: 302

Group type: COMPARATOR
Intervention: Hb within the range
Number of subjects: 302
Study: 30861296

Group type: EXPERIMENTAL
Intervention: Bioresponse system
Number of subjects: 4
Study: 27483393

Group type: EXPERIMENTAL
Intervention: rs3811321 (chromosome 14)
Number of subjects: 1638

Group type: EXPERIMENTAL
Intervention: rs6565887 (chromosome 18)
Number of subjects: 1638

Group type: EXPERIMENTAL
Intervention: Multivariable adjustments for rs3811321 and rs6565887
Number of subjects: 1638
Study: 25997115

Group type: EXPERIMENTAL
Intervention: PF-04958242 (0.27 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-04958242 (0.35 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23514433

Group type: EXPERIMENTAL
Intervention: Rituximab + methotrexate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo + methotrexate
Number of subjects: 31
Study: 21781980

Group type: EXPERIMENTAL
Intervention: Fasting Calorie Restriction (FCR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study: 19619766

Group type: EXPERIMENTAL
Intervention: CABG plus MVR
Number of subjects: 102

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 102
Study: 17556694

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D2/d
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 60,000 IU vitamin D2/mo
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 178
Study: 15453968

Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study: 11432886

Group type: EXPERIMENTAL
Intervention: IV IL‐2 (18.0 MU/m(2))
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: SC IL‐2 (5.0 mU/m(2))
Number of subjects: 81
Study: 9738515

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 7527107

Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg/day
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg/day
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Combination of trandolapril 2 mg/day and HCTZ 25 mg/day
Number of subjects: 205
Study: 2501093

Group type: EXPERIMENTAL
Intervention: GTN patch (7.5 mg GTN (24h)‐1)
Number of subjects: 40
Study: 31533554

Group type: EXPERIMENTAL
Intervention: Abortion stigma
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Contraceptive use stigma
Number of subjects: 1207
Study: 27511058

Group type: EXPERIMENTAL
Intervention: Interesterified PSt/PK (80:20) fat blend (50g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-interesterified PSt/PK fat blend (50g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both meals (IE and non-IE)
Number of subjects: 12
Study: 25876297

Group type: EXPERIMENTAL
Intervention: Epidrum
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study: 23338815

Group type: EXPERIMENTAL
Intervention: Exercise intervention (40 min/school day of physical education)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control (60 min/week of physical education)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 446
Study: 21290201

Group type: EXPERIMENTAL
Intervention: 3% saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 60
Study: 19199105

Group type: COMPARATOR
Intervention: Standard decongestive lymphatic therapy (DLT) with pneumatic compression (PC) (bandage group, N = 21)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Modified DLT with Kinesio tape (K-tape) and pneumatic compression (PC) (K-tape group, N = 20)
Number of subjects: 41
Study: 17045674

Group type: EXPERIMENTAL
Intervention: Sorin Freedom prosthesis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Carpentier-Edwards Perimount prosthesis
Number of subjects: 80
Study: 15530259

Group type: EXPERIMENTAL
Intervention: Pd 103 brachytherapy with 90 Gy plus 44 Gy supplemental beam radiation
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Pd 103 brachytherapy with 115 Gy plus 20 Gy supplemental beam radiation
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Presence of Gleason pattern 5 cancer
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Patients with biochemical failure
Number of subjects: 152
Study: 11573598

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 25
Study: 15613165

Group type: EXPERIMENTAL
Intervention: Frequent headache (overall prevalence)
Number of subjects: 13343

Group type: EXPERIMENTAL
Intervention: Frequent headache in Caucasians
Number of subjects: 13343

Group type: EXPERIMENTAL
Intervention: Frequent headache by education level
Number of subjects: 13343

Group type: EXPERIMENTAL
Intervention: Chronic tension-type headache
Number of subjects: 13343

Group type: EXPERIMENTAL
Intervention: Frequent headache with migrainous features
Number of subjects: 13343

Group type: EXPERIMENTAL
Intervention: Unclassified frequent headache
Number of subjects: 13343

Group type: EXPERIMENTAL
Intervention: Migraine criteria
Number of subjects: 13343
Study: 7871360

Group type: EXPERIMENTAL
Intervention: Miconazole 55 mg/g denture lacquer applied once on the mucosal denture surface
Number of subjects: 0

Group type: COMPARATOR
Intervention: Miconazole 2% gel applied four times daily for 2 weeks
Number of subjects: 0
Study: 2904394

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31072195

Group type: EXPERIMENTAL
Intervention: L-shaped silicone prosthesis (group A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: e-PTFE graft (group B)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: silicone graft using the modified double 'V' method (group C)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: e-PTFE graft using the modified double 'V' method (group D)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 200
Study: 31233260

Group type: EXPERIMENTAL
Intervention: Perceptual discrimination training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28350759

Group type: EXPERIMENTAL
Intervention: Trans-resveratrol (75 mg, twice daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25183409

Group type: EXPERIMENTAL
Intervention: Intraperitoneal drainage
Number of subjects: 137

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 137
Study: 24353564

Group type: EXPERIMENTAL
Intervention: Mat Pilates exercise program (8 weeks, 3 times weekly)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no structured exercises)
Number of subjects: 50
Study: 21529375

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy (VRET)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 20
Study: 17365072

Group type: EXPERIMENTAL
Intervention: Cognitive hypnotherapy (CH)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 84
Study: 15838655

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 21
Study: 12060028

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 31
Study: 9797850

Group type: EXPERIMENTAL
Intervention: CRH administration (100 micrograms hCRH)
Number of subjects: 30